Drug Profile
TI 1001
Alternative Names: MAR-T/GP100 - Timmune Biotech; MAR-T/GP100 with TriTE - Timmune Biotech; TI-1001Latest Information Update: 28 Oct 2021
Price :
$50
*
At a glance
- Originator Timmune Biotech
- Class CAR-T cell therapies; Gene therapies; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Oct 2021 No recent reports of development identified for preclinical development in Cancer in China (Parenteral)
- 13 Sep 2017 Preclinical trials in Cancer in China (Parenteral) before September 2017 (Timmune Biotech pipeline, September 2017)